Compare Fresenius Kabi Onco. with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs ASTRAZENECA PHARMA - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. ASTRAZENECA PHARMA FRESENIUS KABI ONCO./
ASTRAZENECA PHARMA
 
P/E (TTM) x 22.1 127.0 17.4% View Chart
P/BV x 3.1 38.9 8.0% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 FRESENIUS KABI ONCO.   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
ASTRAZENECA PHARMA
Mar-18
FRESENIUS KABI ONCO./
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs1761,278 13.8%   
Low Rs79883 8.9%   
Sales per share (Unadj.) Rs37.7228.4 16.5%  
Earnings per share (Unadj.) Rs5.110.4 49.1%  
Cash flow per share (Unadj.) Rs6.716.3 41.3%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs42.598.8 43.1%  
Shares outstanding (eoy) m158.2325.00 632.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.44.7 71.4%   
Avg P/E ratio x25.0104.2 24.0%  
P/CF ratio (eoy) x18.966.4 28.5%  
Price / Book Value ratio x3.010.9 27.3%  
Dividend payout %00-   
Avg Mkt Cap Rs m20,13527,008 74.6%   
No. of employees `0001.21.4 85.0%   
Total wages/salary Rs m7031,535 45.8%   
Avg. sales/employee Rs Th5,176.24,210.9 122.9%   
Avg. wages/employee Rs Th610.41,132.2 53.9%   
Avg. net profit/employee Rs Th699.6191.1 366.1%   
INCOME DATA
Net Sales Rs m5,9635,710 104.4%  
Other income Rs m18123 14.7%   
Total revenues Rs m5,9815,833 102.5%   
Gross profit Rs m1,430463 308.9%  
Depreciation Rs m258147 175.0%   
Interest Rs m-260-   
Profit before tax Rs m1,216438 277.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m342179 191.3%   
Profit after tax Rs m806259 311.0%  
Gross profit margin %24.08.1 295.8%  
Effective tax rate %28.140.8 68.9%   
Net profit margin %13.54.5 297.8%  
BALANCE SHEET DATA
Current assets Rs m5,1023,209 159.0%   
Current liabilities Rs m2,3852,070 115.3%   
Net working cap to sales %45.620.0 228.2%  
Current ratio x2.11.6 137.9%  
Inventory Days Days15072 207.4%  
Debtors Days Days11335 324.4%  
Net fixed assets Rs m5,148790 651.4%   
Share capital Rs m15850 316.4%   
"Free" reserves Rs m6,5562,419 271.0%   
Net worth Rs m6,7322,469 272.6%   
Long term debt Rs m9520-   
Total assets Rs m10,3884,605 225.6%  
Interest coverage x-45.8NM-  
Debt to equity ratio x0.10-  
Sales to assets ratio x0.61.2 46.3%   
Return on assets %7.55.6 133.4%  
Return on equity %12.010.5 114.1%  
Return on capital %14.617.7 82.3%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,298300 1,768.5%   
Fx outflow Rs m1,7722,015 88.0%   
Net fx Rs m3,525-1,715 -205.5%   
CASH FLOW
From Operations Rs m1,27488 1,449.5%  
From Investments Rs m-1,204-94 1,286.5%  
From Financial Activity Rs m-196NA-  
Net Cashflow Rs m-126-6 2,215.8%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 81.0 75.0 108.0%  
Indian inst/Mut Fund % 0.3 0.3 100.0%  
FIIs % 9.6 15.7 61.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 9.1 100.0%  
Shareholders   42,599 12,856 331.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   SUVEN LIFE SCIENCES  SUN PHARMA  IPCA LABS  TTK HEALTHCARE  NEULAND LABS  

Compare FRESENIUS KABI ONCO. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty End Flat; Asian Paints, UPL & ITC Among Top Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY21); Net Profit Down 21.2% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

Is Intraday Trading For You?(Fast Profits Daily)

May 13, 2021

Do you think you have what it takes to be an intraday trader? Find out in this video.

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 8-QTR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS